Our laboratory is interested in characterizing the role of the Hippo signaling pathway in cancer. While this pathway is a key regulator of organ size and embryonic development, the past decade has highlighted its function in driving tumorigenesis and drug resistance mediated by the aberrant activation of YAP/TAZ-TEAD transcriptional complexes. With significant research reported thus far in the dissection of upstream regulators and downstream targets of the pathway, we are still lacking a detailed mechanistic understanding of the pathway in different disease-relevant settings.
An extensive combination of large-scale functional genomics screens, CRISPR/Cas9 genome editing, epi-/genomic profiling and mass spectrometry-based proteomics will enable the dissection of novel vulnerabilities in cancer indications driven by aberrant Hippo pathway activity and provide unprecedented resolution of YAP-TAZ/TEAD contributions in disease.
We are working in close collaboration with different departments within NIBR Giorgio Galli’s lab, (Postdoc Co-Mentor), and offer the opportunity for interactions with academic labs, locally and globally.